Dihexa: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 45 community reports
- โข2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Species Translation | All published Dihexa research is in rodent models (rats). The key study used oral dosing at 1 mg/kg in aged rats and scopolamine-treated rats. Key preclinical papers (Benoist/Kawas 2014 and McCoy/Kawas 2012) were retracted due to data integrity concerns. | Community uses fixed oral doses of 5-40 mg daily in humans. The 1 mg/kg rat dose would translate to approximately 0.16 mg/kg HED (roughly 11 mg for a 70 kg person) using standard allometric scaling. | high Dihexa has never been tested in humans. The entire community protocol is based on extrapolation from rodent data, with key papers retracted. This represents a higher uncertainty level than most peptides. |
| Safety Data | No human safety data exists. Preclinical data is limited. Dihexa potentiates HGF/c-Met signaling, a pathway implicated in cancer progression when dysregulated. | Community uses Dihexa based on perceived cognitive benefits despite the absence of any human safety data. Most users acknowledge the theoretical cancer risk but proceed with short-term use. | high The c-Met/HGF pathway is a known oncogenic signaling axis. While short-term HGF potentiation does not necessarily promote cancer, the theoretical risk is a significant concern that cannot be dismissed without human safety data. |
| Retracted Research | A key 2014 publication by Benoist, Kawas et al. in the Journal of Pharmacology and Experimental Therapeutics was retracted due to data integrity concerns (falsified/fabricated figures). A 2012 McCoy, Kawas et al. paper in the same journal was also retracted. The original 2012 Harding et al. paper in the Journal of Medicinal Chemistry remains unretracted. | Community is partially aware of the retraction but often continues to cite the retracted findings. Some users acknowledge the weakened evidence base while others are unaware of the retraction. | high The retraction of a key supporting paper significantly weakens the preclinical evidence base for Dihexa. Community users should be aware that some commonly cited claims originate from retracted research. |
Compare these community approaches with published research findings.
Community Protocols
Low-Dose Oral Protocol
Common- Route
- Oral
- Dose
- 5-10 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks (with cycling)
Starting dose for new users; taken orally based on reported oral bioavailability in animal studies
Moderate Oral Protocol
Common- Route
- Oral
- Dose
- 10-20 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Dose used by more experienced users; some report diminishing returns above 20 mg
Sublingual Protocol
Niche- Route
- Sublingual
- Dose
- 5-10 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Some users try sublingual for potentially improved absorption; no data supporting this route
Cycling Protocol
Niche- Route
- Oral
- Dose
- 10-20 mg
- Frequency
- Once daily
- Duration
- 90 days on, 30 days off
Extended cycling protocol; longer on-period due to proposed mechanism of promoting lasting structural changes (synaptogenesis)
Stacking Patterns
Dihexa + Semax Cognitive Stack
NicheCombining Dihexa for synaptogenesis and structural brain changes with Semax for BDNF upregulation and acute cognitive enhancement
Dihexa + Cerebrolysin Neuroprotective Stack
NicheAdvanced neuroprotective combination targeting multiple neurotrophic pathways; used by a small subset of experienced nootropic users
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 45+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Nootropics|Dihexa experience reports and safety discussions(accessed 2026-02-16)
- Reddit r/Peptides|Dihexa dosing protocol discussions(accessed 2026-02-16)
- Nootropics On Reddit (Tumblr archive)|Dihexa - A 1-Week Trial, In Review(accessed 2026-02-16)
- Nootropics On Reddit (Tumblr archive)|Dihexa experiences compilation(accessed 2026-02-16)
- Swolverine|Dihexa Peptide benefits, mechanism, and cognitive risks explained(accessed 2026-02-16)
- Nootroholic|Dihexa Peptide Masterclass guide(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Dihexa (PNB-0408). The information below is gathered from nootropic forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
Dihexa is one of the more controversial compounds used in the nootropic community. It has never been tested in humans, key preclinical papers were retracted for data integrity issues, and its mechanism of action (potentiating HGF/c-Met signaling) raises theoretical cancer risk concerns. Despite these issues, a subset of the nootropics community has experimented with it based on the remaining preclinical data showing cognitive enhancement in aged rats.
Understanding Protocol Divergence#
No Human Data Foundation#
The most critical aspect of Dihexa community use is that all protocols are extrapolated entirely from rodent studies. There are no human pharmacokinetic, safety, or efficacy data. This places Dihexa in a higher-risk category than peptides like Selank or Semax, which at least have human clinical trial data from Russian studies.
Retracted Research#
Two key papers in the Journal of Pharmacology and Experimental Therapeutics were retracted due to data integrity concerns: Benoist, Kawas et al. (2014) and McCoy, Kawas et al. (2012). A Washington State University investigation found falsified and/or fabricated data in figures. The original 2012 Harding et al. paper in the Journal of Medicinal Chemistry remains unretracted, but the retractions weaken the overall evidence base. Community discussions sometimes cite findings from retracted papers without awareness of their status.
Cancer Risk Considerations#
Dihexa potentiates the HGF/c-Met signaling pathway. This pathway, when dysregulated, is a well-established driver of cancer progression, metastasis, and drug resistance. While short-term potentiation of HGF signaling in the brain may not translate to cancer risk, this remains a theoretical concern that has not been addressed by any safety study.
Commonly Reported Outcomes#
Community reports for Dihexa are more variable and less consistent than for most peptides:
- Vivid dreams: The most consistently reported effect across users
- Cognitive enhancement: Some users report improved creativity, verbal fluency, and critical thinking, but reports are inconsistent
- Social cognition: A subset of users report improved social awareness and communication
- No effect: A notable proportion of users report no perceptible cognitive changes
- Headaches: Reported at higher doses by some users
Important Caveats#
- No human clinical trials have ever been conducted with Dihexa
- Key supporting papers were retracted for data integrity concerns
- The HGF/c-Met pathway is a known oncogenic signaling axis
- Cognitive enhancement in healthy individuals is extremely difficult to assess objectively
- Product quality and identity verification are significant concerns for a compound without pharmaceutical-grade sources
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Dihexa
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.